1. Academic Validation
  2. Targeting p53 for the treatment of cancer

Targeting p53 for the treatment of cancer

  • Semin Cancer Biol. 2022 Feb;79:58-67. doi: 10.1016/j.semcancer.2020.07.005.
Michael J Duffy 1 Naoise C Synnott 2 Shane O'Grady 3 John Crown 4
Affiliations

Affiliations

  • 1 UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland. Electronic address: MICHAEL.J.DUFFY@UCD.IE.
  • 2 UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; Division of Cancer Epidemiology and Genetics, and Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Rockville, MD, USA.
  • 3 UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • 4 Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
Abstract

Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two principal mechanisms are responsible for this dysfunction; mutation and downregulation of wild-type p53 mediated by MDM2/MDM4. Because of its almost universal inactivation in malignancy, p53 is a highly attractive target for the development of new Anticancer drugs. Although multiple strategies have been investigated for targeting dysfunctional p53 for Cancer treatment, only 2 of these have so far yielded compounds for testing in clinical trials. These strategies include the identification of compounds for reactivating the mutant form of p53 back to its wild-type form and compounds for inhibiting the interaction between wild-type p53 and MDM2/MDM4. Currently, multiple p53-MDM2/MDM4 antagonists are undergoing clinical trials, the most advanced being idasanutlin which is currently undergoing testing in a phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia. Two mutant p53-reactivating compounds have progressed to clinical trials, i.e., APR-246 and COTI-2. Although promising data has emerged from the testing of both MDM2/MDM4 inhibitors and mutant p53 reactivating compounds in preclinical models, it is still unclear if these agents have clinical efficacy. However, should any of the compounds currently being evaluated in clinical trials be shown to have efficacy, it is likely to usher in a new era in Cancer treatment, especially as p53 dysfunction is so prevalent in human cancers.

Keywords

APR-246; COTI-2; MDM2; MDM4; p53.

Figures
Products